 |
Prospector
Profile
3-5-005
|
| |
| Emisphere Technologies, Inc. |
NAICS |
325412 |
| 765 Old Saw Mill River Rd.,
Tarrytown, NY 10591 |
Description |
Pharmaceutical Preparation Mfg. |
| (914) 347-2220 |
Employees |
111 |
| http://www.emisphere.com/ |
Revenue |
(mil) |
7.2600 |
| |
Income |
(mil) |
-41.7700 |
| |
Assets |
(mil) |
28.0900 |
| |
Liability |
(mil) |
34.2000 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
IP Asset Sale
|
| |
|
Event:
Emisphere Technologies, Inc., reported that it has sold to MannKind Corporation certain Emisphere patents and a patent application relating to diketopiperazine technology for a total purchase price of $2.5 million. An initial
$1.5 million payment is due three business days after the parties sign a Patent Purchase Agreement.
|
| |
|
Intellectual Property:
The Company seeks patent protection on various aspects of its proprietary chemical and pharmaceutical delivery technologies, including, but not limited to, the delivery agent compounds and their generic structures which encompass Emisphere`s Delivery Agents. The Company has patents and patent applications for delivery agents currently used in conjunction with insulin, heparin, LMWH, sCT, PTH 1-34, rhGH and numerous other pharmaceutical and biotechnology products. As of December 31, 2006, the Company has 90 granted patents in the U.S. and had other patents issued or applications pending in various countries around the world. As of December 31, 2006, the Company has 84 patent applications relating to drug delivery technology pending in the U.S. The Company has pursued strategic international protection with approximately 140 patents and 353 patent applications pending internationally in a total of 45 different countries. The majority of the filings are made in Australia, Canada, the European Patent Office, Japan, and Mexico. The Company has U.S. issued patents and/or pending patent applications including Elaprin(TM) (oral heparin) and salmon calcitonin. In addition, there are nine trademarks currently granted by the U.S. Patent and Trademark office and 19 trademarks granted by foreign country patent offices. [SEC Filing 10-KSB 03-05-07]
|
| |
|
Description:
Emisphere Technologies, Inc., is a biopharmaceutical company specializing in the oral delivery of therapeutic macromolecules and other compounds that are not deliverable by oral means.
|
| |
|
Officers:
Michael M. Goldberg (Chair & CEO); William Rumble (Controller & Prin. Acctg. Officer); Elliot M. Maza (CFO); Howard M. Pack (Dir.); Mark H. Rachesky (Dir.); Michael Weiser (Dir.); Stephen K. Carter (Dir.); John D. Harkey, Jr. (Dir.)
|
| |
|
Auditor:
PricewaterhouseCoopers LLP
|
| |
|
Securities:
Common Stock Symbol EMIS; NasdaqGM; 30,336,928 common shares outstanding as of November 1, 2007.
|
| |
| |
| |
| return to main page |
|
|
